Abstract:Background: The use of vonoprazan (VPZ) has improved the Helicobacter pylori (H. pylori) eradication therapy in Japan. There is no agreement on the dosage and frequency of amoxicillin administration in the VPZ dual treatment in China. We aimed to investigate the clinical effectiveness and safety of 3 treatment regimens using VPZ as an acid-suppressing medication to eradicate H. pylori.Methods: This experiment involved an open, multicenter, randomized, and parallel controlled clinical investigation. A total of 230 newly diagnosed H. pylori-infected patients were then randomly assigned to 1 of 3 groups: (I) H-VA (high-dose amoxicillin combined with VPZ): VPZ 20 mg b.i.d with amoxicillin 750 mg q.i.d for 7 days; (II) L-VA (low-dose amoxicillin combined with VPZ): VPZ 20 mg b.i.d plus amoxicillin 500 mg q.i.d for 7 days; (III) VAC (amoxicillin combined with VPZ and clarithromycin): VPZ 20 mg b.i.d plus amoxicillin 750 mg plus clarithromycin 500 mg for 7 days. At least 4 weeks after treatment, the urea breath test (UBT) was reexamined. The effectiveness of various regimens was assessed based on compliance, safety, and eradication rate.Results: The regimen effectiveness was 63.5% (54/85) in the H-VA group, 58.3% (49/84) in the L-VA group, and 60.7% (37/61) in the VAC group, according to intention to treat (ITT) analysis. According to per protocol (PP) analysis, the eradication rate of the H-VA group was 65.1% (54/83), that of the L-VA group was 66.2% (49/74), and that of the VAC group was 64.9% (37/57). There was no discernible difference in the eradication rate across the 3 regimens, as shown by the results of ITT analysis (χ2=0.032, P=0.984) and PP analysis (χ2=0.480, P=0.786). The rate of adverse effect was 16.90% in the H-VA group, 13.20% in the L-VA group, and 24.10% in the VAC group. There was no discernible difference in the incidence of adverse effect between the three groups (χ2=2.784, P=0.266).Conclusions: None of the 7-day elimination regimens investigated in this study, which included the acid-suppressing medicine VPZ and either a dual treatment paired with amoxicillin, or a triple treatment combined with amoxicillin and clarithromycin, achieved an acceptable eradication rate of H. pylori. Further research is required to identify an effective and safe treatment regimen.Trial Registration: Chinese Clinical Trial Registry identifier: ChiCTR2000040955.

Clinical randomized control trail on rescue regimens for helicobacter pylori-positive patients treated failure by a first-line eradication regimen

Efficacy of quadruple therapy with clarithromycin based on faecal molecular antimicrobial susceptibility tests as first-line treatment for <i>Helicobacter pylori</i> infection: a protocol of a single-centre, single-blind, randomised clinical trial in China

Current Status of Helicobacter Pylori Eradication and Risk Factors for Eradication Failure

Short-term Outcomes and Intermediate-Term Follow-Up of Helicobacter Pylori Infection Treatment for Naïve Patients: a Retrospective Observational Study.

Quadruple Therapy with Vonoprazan 20 Mg Daily As a First-Line Treatment for Helicobacter Pylori Infection: A Single-Center, Open-Label, Noninferiority, Randomized Controlled Trial.

Long-term Therapeutic Effect of Triple Therapy Consisted of Omeperazole,clarithromycin and Amoxycillin in Children with Helicobacter Pylori Infection and Approach to Re-Treatment after Failure of the Treatment

Is Tailored Therapy Based on Antibiotic Susceptibility Effective ? a Multicenter, Open-Label, Randomized Trial

Eradication rate and safety of a "simplified rescue therapy": 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of <i>Helicobacter pylori</i> infection previously failed in eradication: A real-world, retrospective clinical study in China

Eradication rate and safety of a "simplified rescue therapy": 14-day vonoprazan and amoxicillin dual regimen as rescue therapy on treatment of Helicobacter pylori infection previously failed in eradication: A real-world, retrospective clinical study in China

Comparative Effectiveness And Tolerance Of Treatments For Helicobacter Pylori: Systematic Review And Network Meta-Analysis

A randomized clinical study on the efficacy of vonoprazan combined with amoxicillin duo regimen for the eradication of Helicobacter pylori

Comparative Study on Eradication Therapy of 1 440 Newly Diagnosed Patients with Helicobacter Pylori Infection

Eradication Treatment of Helicobacter pylori Infection Based on Molecular Pathologic Antibiotic Resistance

Clinical Impact of High-dose Esomeprazole-amoxicillin Dual Therapy As Rescue Treatment for Helicobacter Pylori Infection

Efficacy and safety of vonoprazan-amoxicillin dual therapy for Helicobacter pylori first-line treatment: a single-center, randomized, controlled trial

The efficacy of vonoprazan combined with different dose amoxicillin on eradication of Helicobacter pylori: an open, multicenter, randomized clinical study

Efficacy and Safety of Modified Dual Therapy as the First-line Regimen for the Treatment of <i>Helicobacter pylori</i> Infection A Meta-Analysis of Randomized Controlled Trials

Newer Therapies for Refractory Helicobacter pylori Infection in Adults: A Systematic Review

Identifying the Best Regimen for Primary Eradication of Helicobacter Pylori: Analysis of 240 Cases.

[Efficacy and Safety of 14-Day Amoxicillin and Furazolidone-Based Quadruple Rescue Regimen for Eradication of Helicobacter Pylori: a Retrospective Study].

Salvage Therapies after Failure of Helicobacter Pylori Eradication with Ranitidine Bismuth Citrate-Based Therapies